Idelvion
albutrepenonacog alfa · CSL Behring GmbH
ORPHAN AUTHORISED IN THE EUWhat Idelvion is used for
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Idelvion
- Active substance
- albutrepenonacog alfa
- Disease area
- Hemophilia B
- Medicine group
- Antihemorrhagics
- ATC code
- B02BD04
- Marketing authorisation holder
- CSL Behring GmbH
- Authorised in the EU since
- 2016
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Idelvion used for?
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
What is the active substance in Idelvion?
Idelvion contains albutrepenonacog alfa.
Who makes Idelvion?
The EU marketing authorisation holder is CSL Behring GmbH.
Is Idelvion an orphan medicine?
Yes. Idelvion is designated an orphan medicine in the EU, for a rare disease (Hemophilia B).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU